Sentences with phrase «in epithelial ovarian cancer»

Sulforaphane induces cell cycle arrest by protecting RB - E2F - 1 complex in epithelial ovarian cancer cells.

c. Epigenetic approaches to primer for and / or synergize with immunological therapy in epithelial ovarian cancer.

a. Mechanism - guided therapeutic strategies for genetic alterations that affect the SWI / SNF chromatin remodeling complex in epithelial ovarian cancer (such as ARID1A mutation in clear cell and endometrioid subtypes of ovarian cancer, and CARM1 amplification / overexpression in high - grade serous ovarian cancer).

In collaboration with the Institut Curie hospital, we are currently investigating origin and consequences of centrosome abnormalities in epithelial ovarian cancers (EOC).

Not exact matches

This discovery is a result of research on the effects of ONA on a preclinical model of epithelial ovarian cancer (EOC) both in vivo and in vitro.

They also found differences in the types of bacteria in the upper reproductive tracts of women with and without epithelial ovarian cancer.

In the new study, DrugPredict suggested non-steroidal anti-inflammatory drugs, also known as NSAIDs, could have applications for epithelial ovarian cancer.

In the Oncogene study, DrugPredict produced a prioritized list of 6,996 chemicals with potential to treat epithelial ovarian cancer.

A total of 640 women in the MMS group had surgery for suspected cancer, of whom 133 women had invasive epithelial ovarian cancers (iEOC).

«We found that women who consume foods high in two sub-groups of powerful substances called flavonoids — flavonols and flavanones — had a significantly lower risk of developing epithelial ovarian cancer.

Therefore, new treatment modalities and paradigms are needed in order to significantly improve the prognosis of women diagnosed with epithelial ovarian cancer.

In that randomized, double - blind, placebo - controlled, phase III trial, 561 patients with recurrent epithelial ovarian, fallopian tube, or primary peritoneal cancer who were in complete or partial response to platinum - based chemotherapy were treated with either rucaparib 600 mg orally twice daily (372 patients) or to placebo (189 patientsIn that randomized, double - blind, placebo - controlled, phase III trial, 561 patients with recurrent epithelial ovarian, fallopian tube, or primary peritoneal cancer who were in complete or partial response to platinum - based chemotherapy were treated with either rucaparib 600 mg orally twice daily (372 patients) or to placebo (189 patientsin complete or partial response to platinum - based chemotherapy were treated with either rucaparib 600 mg orally twice daily (372 patients) or to placebo (189 patients).

Large - scale genomic studies have shown that half of epithelial ovarian cancers (EOCs) have alterations in genes regulating homologous recombination (HR) repair.

Biological Function of Ribosomal Protein L10 on Cell Behavior in Human Epithelial Ovarian Cancer Jimin Shi, Lingyun Zhang, Daibing Zhou, Jinguo Zhang, Qunbo Lin, Wencai Guan, Jihong Zhang, Weimin Ren, Guoxiong Xu J. Cancer 2018; 9 (4): 745 - 756.

The LION trial randomized 650 patients with advanced epithelial ovarian cancer and macroscopic complete resection to either systematic pelvic and para-aortic LNE (323 patients in intention - to - treat cohort), or no LNE (324 patients in intention - to - treat cohort).

The sixteen chapters of Advances in Ovarian Cancer Management present a concise, timely and comprehensive overview on the current status of the etiology, diagnosis and treatment of women with epithelial ovarian Ovarian Cancer Management present a concise, timely and comprehensive overview on the current status of the etiology, diagnosis and treatment of women with epithelial ovarian cCancer Management present a concise, timely and comprehensive overview on the current status of the etiology, diagnosis and treatment of women with epithelial ovarian ovarian cancercancer.

ZEJULA is the first and only once - daily PARP inhibitor for the maintenance treatment of adult patients with recurrent epithelial ovarian, fallopian tube, or primary peritoneal cancer who are in a complete or partial response to platinum - based chemotherapy.1 - 3

ZEJULA is indicated for the maintenance treatment of adult patients with recurrent epithelial ovarian, fallopian tube, or primary peritoneal cancer who are in a complete or partial response to platinum - based chemotherapy.

Zhang is committed to finding a cure for epithelial ovarian cancer, the most lethal gynecological malignancy in the developed world.

In particular, the lab investigates how alterations in epigenetics — or the heritable changes that affects gene expression without alterations in the underlying DNA sequence — contribute to epithelial ovarian canceIn particular, the lab investigates how alterations in epigenetics — or the heritable changes that affects gene expression without alterations in the underlying DNA sequence — contribute to epithelial ovarian cancein epigenetics — or the heritable changes that affects gene expression without alterations in the underlying DNA sequence — contribute to epithelial ovarian cancein the underlying DNA sequence — contribute to epithelial ovarian cancer.

A class of drugs called EZH2 inhibitors are currently in clinical development for both hematological malignancies and solid tumors and may be effectively targeted to epithelial ovarian cancers overexpressing the CARM1 protein.

FORWARD1: A Randomized, Open Label Phase 3 Study to Evaluate the Safety and Efficacy of Mirvetuximab Soravtansine (IMGN853) Versus Investigator's Choice of Chemotherapy in Women with Folate Receptor Alpha - Positive Advanced Epithelial Ovarian Cancer, Primary Peritoneal Cancer or Fallopian Tube Cancer

The FDA has granted approval of rucaparib for maintenance therapy in patients with recurrent epithelial ovarian, fallopian tube, or primary peritoneal cancer.

In effect, this cucumber intervention reversed the biomarkers of metabolic syndrome, the precursor to cardiovascular disease as well as insulin - dependent diabetes, polycystic ovarian syndrome (PCOS), non-alcoholic fatty liver disease (NAFLD), and epithelial cell cancers.